Cinven takes majority stake in Synlab

The acquisition of Synlab by Cinven from BC Partners represents a landmark transaction in the European healthcare services sector, following closely on the heels of Cinven’s acquisition of the French group Labco. The strategic rationale for the deal is the immediate merger of Synlab and Labco to create a dominant pan-European champion in medical diagnostics. This "buy-and-build" strategy is designed to exploit the vast potential for consolidation in a European market where the top two providers previously held only a small fraction of the total market share. The merger combines Synlab’s strong presence in Germany and Northern Europe with Labco’s leadership in France and Southern Europe, resulting in a business with minimal geographic overlap. The partnership is focused on scaling the group’s annual clinical test volume and expanding its international reach into new markets across four continents. By institutionalizing the management and providing a platform for further bolt-on acquisitions, the deal positions the combined entity as a vital partner for healthcare professionals and hospitals seeking high-quality, efficient diagnostic services at scale. This investment highlights the trend of private equity driving industrial logic in the healthcare space to professionalize and internationalize specialized medical services.

The acquisition of Synlab is part of the growth strategy of Cinven, which already has several external growth operations under its belt, notably Tractel in 2015.